Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women

Abstract

High-risk human papillomaviruses (HR-HPV) are the necessary cause of cervical carcinomas. To determine whether HPR-HPV DNA detection in primary routine screening could represent a sensitive and reliable technique for the detection of high-grade squamous intraepithelial lesions (HGSIL), laboratory analysis using 2 cytologic techniques (conventional and liquid-based), HPV testing with Hybrid Capture II assay (HC-II), followed by colposcopic examination of women with abnormal cervical finding and/or persistent HR-HPV infection, was conducted in 7932 women who had routine cervical examination. The sensitivity of HPV testing for detecting a histologically proven HGSIL was 100%, higher than that of conventional (68.1%) and liquid-based (87.8%) cytology. The low specificities of 85.6% and 87.3% of HPV testing slightly increased to 88.4% and 90.1% if HPV testing was reserved for woman >30 years old. The quantitative approach provided by the HC-II assay for the assessment of the viral load was not reliable for predicting HGSIL in normal smears. HR-HPV testing could be proposed in primary screening in association with cytology. With conventional cytology it significantly improves the detection of HGSIL. With the use of the same cervical scrape for HPV testing and liquid-based cytology, HR-HPV testing would allow to select positive samples treated in a second time for cytology which gives a good specificity.

References 40

1. 1.

   Adam E., Kaufman R. H., Berkova Z., Icenogle J., Reeves W. C. Is human papillomavirus testing an effective triage method for detection of high-grade (grade 2 or 3) cervical intraepithelial neoplasia? Am J Obstet Gynecol. 1998;178(6):1235-1244.

   Not in our library10.1016/s0002-9378(98)70328-x

2. 2.

   Bosch F. X., Manos M. M., Muñoz N., Sherman M., Jansen A. M., Peto J., Schiffman M. H., Moreno V., Kurman R., Shah K. V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87(11):796-802.

   Not in our library10.1093/jnci/87.11.796

3. 3.

   Clavel C., Bory J. P., Rihet S., Masure M., Duval-Binninger I., Putaud I., Lorenzato M., Quereux C., Birembaut P. Comparative analysis of human papillomavirus detection by hybrid capture assay and routine cytologic screening to detect high-grade cervical lesions. Int J Cancer. 1998;75(4):525-528.

   Not in our library10.1002/(sici)1097-0215(19980209)75:4<525::aid-ijc6>3.0.co;2-v

4. 4.
   Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women · 1999

   No notice
5. 5.

   Clavel C., Masure M., Putaud I., Thomas K., Bory J. P., Gabriel R., Quereux C., Birembaut P. Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions. J Clin Pathol. 1998;51(10):737-740.

   Not in our library10.1136/jcp.51.10.737

6. 6.

   Cox J. T., Lorincz A. T., Schiffman M. H., Sherman M. E., Cullen A., Kurman R. J. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 1995;172(3):946-954.

   Not in our library10.1016/0002-9378(95)90026-8

7. 7.
   HPV testing in primary screening of older women · 1999

   No notice
8. 8.

   Cuzick J., Sasieni P., Davies P., Adams J., Normand C., Frater A., van Ballegooijen M., van den Akker-van Marle E. A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. Br J Cancer. 2000;83(5):561-565.

   Not in our library10.1054/bjoc.2000.1375

9. 9.

   Cuzick J., Szarewski A., Terry G., Ho L., Hanby A., Maddox P., Anderson M., Kocjan G., Steele S. T., Guillebaud J. Human papillomavirus testing in primary cervical screening. Lancet. 1995;345(8964):1533-1536.

   Not in our library10.1016/s0140-6736(95)91086-7

10. 10.
    Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia · 1994

    No notice
11. 11.

    Franco E. L., Villa L. L., Sobrinho J. P., Prado J. M., Rousseau M. C., Désy M., Rohan T. E. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;180(5):1415-1423.

    Not in our library10.1086/315086

12. 12.

    Gaarenstroom K.N., Melkert P., Walboomers J.M.M., Van Den Brule A.J.C., Van Bommel P.F.J., Meyer C.J.L.M., Voorhorst F.J., Kenemans P., Helmerhorst Th.J.M. Human papillomavirus DNA and genotypes: prognostic factors for progression of cervical intraepithelial neoplasia. Int J Gynecol Cancer. 1994;4(2):73-78.

    Not in our library10.1046/j.1525-1438.1994.04020073.x

13. 13.

    Gustafsson L., Adami H. O. Natural history of cervical neoplasia: consistent results obtained by an identification technique. Br J Cancer. 1989;60(1):132-141.

    Not in our library10.1038/bjc.1989.236

14. 14.

    Herrero R., Hildesheim A., Bratti C., Sherman M. E., Hutchinson M., Morales J., Balmaceda I., Greenberg M. D., Alfaro M., Burk R. D. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000;92(6):464-474.

    Not in our library10.1093/jnci/92.6.464

15. 15.

    Ho G. Y., Bierman R., Beardsley L., Chang C. J., Burk R. D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423-428.

    Not in our library10.1056/nejm199802123380703

16. 16.

    Ho G. Y., Burk R. D., Klein S., Kadish A. S., Chang C. J., Palan P., Basu J., Tachezy R., Lewis R., Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995;87(18):1365-1371.

    Not in our library10.1093/jnci/87.18.1365

17. 17.

    Kaufman R. H., Adam E. Is human papillomavirus testing of value in clinical practice? Am J Obstet Gynecol. 1999;180(5):1049-1053.

    Not in our library10.1016/s0002-9378(99)70593-4

18. 18.

    Koutsky L. A., Holmes K. K., Critchlow C. W., Stevens C. E., Paavonen J., Beckmann A. M., DeRouen T. A., Galloway D. A., Vernon D., Kiviat N. B. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327(18):1272-1278.

    Not in our library10.1056/nejm199210293271804

19. 19.

    Kuhn L., Denny L., Pollack A., Lorincz A., Richart R. M., Wright T. C. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst. 2000;92(10):818-825.

    Not in our library10.1093/jnci/92.10.818

20. 20.

    Liaw K. L., Hildesheim A., Burk R. D., Gravitt P., Wacholder S., Manos M. M., Scott D. R., Sherman M. E., Kurman R. J., Glass A. G. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis. 2000;183(1):8-15.

    Not in our library10.1086/317638

21. 21.

    Lorincz A. T., Reid R., Jenson A. B., Greenberg M. D., Lancaster W., Kurman R. J. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992;79(3):328-337.

    Not in our library10.1097/00006250-199203000-00002

22. 22.

    Manos M. M., Kinney W. K., Hurley L. B., Sherman M. E., Shieh-Ngai J., Kurman R. J., Ransley J. E., Fetterman B. J., Hartinger J. S., McIntosh K. M. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999;281(17):1605-1610.

    Not in our library10.1001/jama.281.17.1605

23. 23.

    Meijer C. J., Helmerhorst T. J., Rozendaal L., van der Linden J. C., Voorhorst F. J., Walboomers J. M. HPV typing and testing in gynaecological pathology: has the time come? Histopathology. 1998;33(1):83-86.

    Not in our library10.1046/j.1365-2559.1998.00436.x

24. 24.

    Papillo J. L., Zarka M. A., St John T. L. Evaluation of the ThinPrep Pap test in clinical practice. A seven-month, 16,314-case experience in northern Vermont. Acta Cytol. 1998;42(1):203-208.

    Not in our library10.1159/000331547

25. 25.

    Peyton C. L., Schiffman M., Lörincz A. T., Hunt W. C., Mielzynska I., Bratti C., Eaton S., Hildesheim A., Morera L. A., Rodriguez A. C. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol. 1998;36(11):3248-3254.

    Not in our library10.1128/jcm.36.11.3248-3254.1998

26. 26.

    Ratnam S., Franco E. L., Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev. 2000;9(9):945-951.

    Not in our library

27. 27.

    Remmink A. J., Walboomers J. M., Helmerhorst T. J., Voorhorst F. J., Rozendaal L., Risse E. K., Meijer C. J., Kenemans P. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer. 1995;61(3):306-311.

    Not in our library10.1002/ijc.2910610305

28. 28.

    Riethmuller D., Gay C., Bertrand X., Bettinger D., Schaal J. P., Carbillet J. P., Lassabe C., Arveux P., Seilles E., Mougin C. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn Mol Pathol. 1999;8(3):157-164.

    Not in our library10.1097/00019606-199909000-00009

29. 29.

    Rozendaal L., Walboomers J. M., van der Linden J. C., Voorhorst F. J., Kenemans P., Helmerhorst T. J., van Ballegooijen M., Meijer C. J. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer. 1996;68(6):766-769.

    Not in our library10.1002/(sici)1097-0215(19961211)68:6<766::aid-ijc13>3.0.co;2-z

30. 30.

    Schiffman M., Herrero R., Hildesheim A., Sherman M. E., Bratti M., Wacholder S., Alfaro M., Hutchinson M., Morales J., Greenberg M. D. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000;283(1):87-93.

    Not in our library10.1001/jama.283.1.87

31. 31.

    Schneider A., Zahm D. M., Kirchmayr R., Schneider V. L. Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection. Am J Obstet Gynecol. 1996;174(5):1534-1541.

    Not in our library10.1016/s0002-9378(96)70602-6

32. 32.

    Sherman M. E., Mendoza M., Lee K. R., Ashfaq R., Birdsong G. G., Corkill M. E., McIntosh K. M., Inhorn S. L., Zahniser D. J., Baber G. Performance of liquid-based, thin-layer cervical cytology: correlation with reference diagnoses and human papillomavirus testing. Mod Pathol. 1998;11(9):837-843.

    Not in our library

33. 33.

    Solomon D., Schiffman M., Tarone R., ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93(4):293-299.

    Not in our library10.1093/jnci/93.4.293

34. 34.

    Stoler M. H. Advances in cervical screening technology. Mod Pathol. 2000;13(3):275-284.

    Not in our library10.1038/modpathol.3880048

35. 35.

    Vernon S. D., Unger E. R., Williams D. Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture. J Clin Microbiol. 2000;38(2):651-655.

    Not in our library10.1128/jcm.38.2.651-655.2000

36. 36.

    Walboomers J. M., Jacobs M. V., Manos M. M., Bosch F. X., Kummer J. A., Shah K. V., Snijders P. J., Peto J., Meijer C. J., Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19.

    Not in our library10.1002/(sici)1096-9896(199909)189:1<12::aid-path431>3.0.co;2-f

37. 37.

    Weintraub J., Morabia A. Efficacy of a liquid-based thin layer method for cervical cancer screening in a population with a low incidence of cervical cancer. Diagn Cytopathol. 2000;22(1):52-59.

    Not in our library10.1002/(sici)1097-0339(200001)22:1<52::aid-dc14>3.0.co;2-#

38. 38.

    Wright T. C., Lorincz A., Ferris D. G., Richart R. M., Ferenczy A., Mielzynska I., Borgatta L. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol. 1998;178(5):962-966.

    Not in our library10.1016/s0002-9378(98)70531-9

39. 39.

    Ylitalo N., Sørensen P., Josefsson A. M., Magnusson P. K., Andersen P. K., Pontén J., Adami H. O., Gyllensten U. B., Melbye M. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet. 2000;355(9222):2194-2198.

    Not in our library10.1016/s0140-6736(00)02402-8

40. 40.

    zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol. 1994;186:131-156.

    Not in our library10.1007/978-3-642-78487-3_8

Cited by papers we hold 5

• The role of human papillomaviruses in carcinogenesis · 2015
  No notice
• Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study · 2008
  No notice
• High-risk HPV type-specific clearance rates in cervical screening · 2007
  No notice
• Analysis of molecular biology techniques for the diagnosis of human papillomavirus infection and cervical cancer prevention Análise de técnicas de biologia molecular para o diagnóstico de infecções causadas por papilomavírus humanos e a prevenção do câncer cervical · 2006
  Not checked
• Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients · 2003
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.